ストックスクリーナーアプリを入手
4.82
6.91%
0.35
前日終値:
$4.47
開ける：
$4.66
24時間の取引高:
410.26K
Relative Volume:
0.63
時価総額：
$1.09B
収益：
$596.48M
当期純損益:
$123.72M
株価収益率:
8.7892
EPS:
0.5484
ネットキャッシュフロー:
$106.59M
1週間 パフォーマンス:
+16.84%
1か月 パフォーマンス:
+34.24%
6か月 パフォーマンス:
+63.66%
1年 パフォーマンス:
+22.85%
1日の値動き範囲:
$4.61
$4.82
1週間の範囲:
$4.11
$4.795
52週間の値動き範囲:
$2.37
$5.28
Curevac N V Stock (CVAC) Company Profile
CVAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
4.82 | 979.44M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
ONC
Beone Medicines Ltd Adr
|
244.99 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.50 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.60 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.08 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-25 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 開始されました | SVB Securities | Outperform |
| 2023-01-19 | アップグレード | UBS | Neutral → Buy |
| 2023-01-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-01-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-06-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Underperform |
| 2021-04-26 | 開始されました | Guggenheim | Neutral |
| 2020-12-10 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-09-08 | 開始されました | Credit Suisse | Neutral |
| 2020-09-08 | 開始されました | Jefferies | Hold |
すべてを表示
Curevac N V (CVAC) 最新ニュース
CureVac: Successful cash burn reduction - marketscreener.com
CureVac (NASDAQ:CVAC) Given “Market Outperform” Rating at JMP Securities - Defense World
D. E. Shaw & Co. Inc. Purchases New Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac (CVAC) Maintains Market Outperform Rating with Stable Price Target | CVAC Stock News - GuruFocus
CureVac stock maintains $10 target from JMP on GBM vaccine outlook - Investing.com UK
Millennium Management LLC Sells 771,136 Shares of CureVac (NASDAQ:CVAC) - Defense World
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business - simplywall.st
We Think CureVac's (NASDAQ:CVAC) Robust Earnings Are Conservative - Yahoo
CureVac First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
CureVac FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
BNP Paribas Financial Markets Takes $585,000 Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac Announces Annual General Meeting for June 2025 - TipRanks
Earnings Beat: CureVac N.V. (NASDAQ:CVAC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
CureVac NV reports results for the quarter ended March 31Earnings Summary - TradingView
CureVac price target lowered to $2 from $2.50 at BofA - TipRanks
CureVac (CVAC): BofA Reduces Price Target Amidst Ongoing Challen - GuruFocus
CureVac N.V. Reports Q1 2025 Financial Results Amid Strategic Restructuring - TipRanks
CureVac Reports Q1 2025 Financial Results Amid Revenue Decline - TipRanks
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction - Benzinga
CVAC Reduces Operating Loss in Q1 2025 Amid Strong Pipeline Progress | CVAC Stock News - GuruFocus
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - ACCESS Newswire
CureVac Secures Major FDA Win for Cancer Drug While Patent Battle Against BioNTech Heats Up - Stock Titan
Curevac Q1 Revenue Eur 900 Thousand - marketscreener.com
CureVac granted favorable decision by European Patent Office vs. BioNTech - TipRanks
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE | CVAC Stock News - GuruFocus
CureVac Secures Critical Second Patent Win vs BioNTechJuly Court Showdown Set for mRNA Rights - Stock Titan
CureVac Secures Key Patent Victory in Litigation with BioNTech - TipRanks
Barclays PLC Has $118,000 Stake in CureVac (NASDAQ:CVAC) - Defense World
CureVac (CVAC) to Release Earnings on Thursday - Defense World
Analysts Offer Valuable Insight On CureVac N.V (CVAC) - Stocksregister
CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy? - Defense World
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - ACCESS Newswire
Geode Capital Management LLC Acquires 22,491 Shares of CureVac (NASDAQ:CVAC) - Defense World
UBS Group Lowers CureVac (NASDAQ:CVAC) Price Target to $12.00 - Defense World
CVAC (CureVac N.V) has impressive results - uspostnews.com
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth - simplywall.st
Legal & General Group Plc Has $359,000 Holdings in CureVac (NASDAQ:CVAC) - Defense World
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
CureVac (CVAC) Target Price Reduced by UBS Analyst | CVAC Stock News - GuruFocus
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating - marketscreener.com
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet - ACCESS Newswire
CureVac N.V (CVAC) Stock: Navigating a Year of Stock Volatility - investchronicle.com
CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s Why - Defense World
Can you still get a good price for CureVac N.V (CVAC) Shares at this point? - uspostnews.com
CureVac (CVAC) to Release Quarterly Earnings on Wednesday - Defense World
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa
Curevac N V (CVAC) 財務データ
収益
当期純利益
現金流量
EPS
1.76%
0.89%
大文字化:
|
ボリューム (24 時間):